Cancer Antigen (CA) 15-3
Also known as: CA 15-3
Use
Quantitative measurement of cancer antigen 15-3
Special Instructions
Values obtained with different assay methods should not be used interchangeably in serial testing. It is recommended that only one assay method be used consistently to monitor each patient's course of therapy. This procedure does not provide serial monitoring and is intended for one-time use only. If serial monitoring is required, please use the serial monitoring number 483404. Patients using high-dose biotin supplements should stop intake at least 72 hours before specimen collection as it may interfere with the test results.
Limitations
The CA 15-3 assay value, regardless of level, should not be interpreted as absolute evidence for the presence or absence of malignant disease. The CA 15-3 assay should be used in conjunction with clinical evaluation and other diagnostic procedures. Variability between methods implies that results from different assays or laboratories may not be comparable. High-dose biotin usage may interfere with test accuracy.
Methodology
Immunoassay (ECLIA)
Biomarkers
LOINC Codes
- 6875-9
- 6875-9
Result Turnaround Time
1 day
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
1 mL
Minimum Volume
0.7 mL
Container
Gel-barrier tube (preferred) or red-top tube
Collection Instructions
If a red-top tube is used, transfer separated serum to a plastic transport tube.
Patient Preparation
Patients should stop biotin consumption at least 72 hours before specimen collection.
Storage Instructions
Store at room temperature.
Causes for Rejection
Citrate plasma specimen; improper labeling
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 14 days |
| Refrigerated | 14 days |
| Frozen | 14 days |
Other tests from different labs that may be relevant